Emrah Can | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award | Professor| Istanbul University | Turkey

Prof. Dr. Emrah Can is a highly accomplished pediatrician and neonatology-focused clinician-scientist recognized for his extensive contributions to neonatal health, pediatric infectious diseases, neonatal sepsis, retinopathy of prematurity, and pediatric critical care. Prof. Dr. Emrah Can completed his medical training at Istanbul University Faculty of Medicine, followed by his medical specialization in Child Health and Diseases at Health Sciences University, İstanbul Bağcılar Training and Research Hospital, where he developed strong clinical expertise in neonatal nutrition, early sepsis biomarkers, high-risk neonatal monitoring, and pediatric intensive care. He progressed academically to the ranks of Associate Professor and Professor through consistent research productivity, clinical excellence, and mentorship. Throughout his career, Prof. Dr. Emrah Can has supervised numerous pediatric specialization theses focused on neonatal sepsis biomarkers, MRSA carriage among hospitalized children, melatonin levels in early sepsis, prognostic tools for pediatric traumatic brain injury, differentiation of lower respiratory tract infection and colonization in tracheostomized children, fetal malnutrition indicators, and hyperbilirubinemia-related risk factors, demonstrating his commitment to developing evidence-based pediatric protocols and training the next generation of pediatric specialists. His research interests include neonatal immunology, inflammation markers, nutritional interventions for premature infants, oxygen affinity biomarkers, neonatal thrombosis, and innovative hypothesis-driven models for predicting neonatal morbidity. His research skills include statistical analysis, advanced clinical data interpretation, hypothesis modeling, neonatal diagnostic model development, and interdisciplinary collaboration. Prof. Dr. Emrah Can has authored impactful publications in reputable journals such as Medical Hypotheses, International Ophthalmology, European Journal of Pediatrics, Pediatric Cardiology, and Journal of Paediatrics and Child Health, contributing significantly to early detection strategies for NEC, ROP, neonatal thrombosis, and hematologic alterations in neonates. His scientific memberships reflect his professional commitment, including active participation in the Pediatric Allergy and Asthma Academy Association, Turkish National Pediatric Association, Child Friends Association, and Turkish Neonatology Association. He has also served in academic administrative roles, including program head positions that highlight his leadership in medical education. Prof. Dr. Emrah Can has received recognition for his academic achievements, research contributions, and involvement in pediatric healthcare improvement initiatives. Overall, Prof. Dr. Emrah Can demonstrates exceptional clinical acumen, research innovation, collaborative engagement, and leadership in pediatric and neonatal medicine, positioning him as a scholar whose contributions continue to shape evidence-based neonatal care, advance scientific understanding of pediatric diseases, and improve health outcomes for vulnerable newborn populations.

Profile:  scopus | ORCID

Featured Publications

  1. Can, E. (2025). Development of a scoring model integrating inflammatory markers for predicting ROP in preterm neonates. International Ophthalmology.

  2. Can, E. (2025). Postnatal hemoglobin P50 as a surrogate marker for hypoxia-driven NEC in preterm infants: A mechanistic hypothesis. Medical Hypotheses.

  3. Can, E. (2025). Phototherapy modifies hematologic markers without inducing inflammation in neonates: A retrospective observational study. European Journal of Pediatrics.

  4. Can, E. (2025). Could parabiotics safely enhance immune maturation and mitigate NEC/sepsis in preterm neonates? Medical Hypotheses.

  5. Can, E. (2025). Early haemoglobin oxygen affinity as a hypothesis-generating marker for retinopathy of prematurity risk in preterm infants. Journal of Paediatrics and Child Health.

  6. Can, E. (2025). Neonatal portal vein thrombosis: A case series from a tertiary NICU. Pediatric Cardiology.

 

Mingyao Liu | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Mingyao Liu | Medicine and Health Sciences | Best Researcher Award

Prof. Mingyao Liu | Medicine and Health Sciences | Best Researcher Award | Professor | University of Toronto | Canada

Prof. Mingyao Liu, MD, MSc, is an internationally recognized biomedical scientist and academic leader renowned for his pioneering contributions to lung injury, transplantation immunology, and regenerative medicine. He currently serves as the James & Mary Davie Chair in Lung Injury, Repair and Regeneration at the University Health Network and as Director of the Institute of Medical Science at the University of Toronto, where he leads multidisciplinary teams advancing translational research in organ preservation and immunomodulation. Prof. Mingyao Liu obtained his M.D. and M.Sc. in Pathophysiology from the Second Military Medical University in Shanghai, China, followed by an intensive postdoctoral fellowship at the SickKids Research Institute in Toronto, Canada, where he began his journey into molecular mechanisms of lung disease and transplant biology. His professional experience spans decades of leadership roles, including Senior Scientist at the Toronto General Hospital Research Institute and Full Professor in the Department of Surgery at the University of Toronto, with cross-appointments in Medicine and Physiology. Prof. Mingyao Liu’s research interests focus on understanding ischemia-reperfusion injury, immune tolerance in organ transplantation, and cellular mechanisms driving lung regeneration. His laboratory employs advanced molecular biology, gene editing, single-cell transcriptomics, and ex vivo organ perfusion systems to identify therapeutic targets that improve graft survival and repair outcomes. His scientific expertise is further reflected through numerous publications in high-impact journals such as Transplantation, Scientific Reports, NPJ Digital Medicine, and The American Journal of Transplantation. Prof. Mingyao Liu has received multiple prestigious awards, including the Queen Elizabeth II Diamond Jubilee Medal, the Premier’s Research Excellence Award, and the Mel Silverman Mentorship Award, highlighting both his research excellence and commitment to nurturing the next generation of scientists. As a dedicated member of numerous professional societies such as the American Thoracic Society, The Transplantation Society, and the International Society of Heart and Lung Transplantation, he plays a significant role in shaping global biomedical research discourse. Prof. Mingyao Liu’s career reflects a rare combination of innovative science, effective leadership, and lifelong mentorship, making him one of the foremost authorities in lung transplant biology. His continued contributions are shaping the future of regenerative medicine through translational discoveries that bridge laboratory innovation with clinical excellence, reinforcing his position as a global leader dedicated to improving outcomes for patients with severe pulmonary diseases.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

  1. Liu, M. (2025). Permissive immunosuppression facilitates the expansion of ex vivo administered regulatory T cells in the lung allograft. Scientific Reports. 1 citation.

  2. Liu, M. (2025). Ischemia/Reperfusion upregulates genes related to PANoptosis in human lung transplants. Transplantation. 3 citations.

  3. Liu, M. (2025). L-Alanyl-L-Glutamine alleviated ischemia-reperfusion injury and primary graft dysfunction in rat lung transplants. Transplantation. 2 citations.

  4. Liu, M. (2025). Ex vivo delivery of recombinant IL-10 to human donor lungs. JHLT Open. 0 citations.

  5. Liu, M. (2025). Protective effects of 10 °C preservation on donor lungs with lipopolysaccharide-induced acute lung injury. Conference Proceedings. 1 citation.

  6. Liu, M. (2024). Improving prognostic accuracy in lung transplantation using unique features of isolated human lung radiographs. NPJ Digital Medicine. 3 citations.

  7. Liu, M. (2024). Ischemia-reperfusion responses in human lung transplants at the single-cell resolution. American Journal of Transplantation. 5 citations.

 

Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award

Prof. Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award | Professor | Chungbuk National University | South Korea

Prof. Yun-Bae Kim, a distinguished professor at the Department of Toxicology, College of Veterinary Medicine, Chungbuk National University, Republic of Korea, is an eminent scholar in the fields of toxicology, neurobiology, and regenerative medicine. Holding both a Doctor of Veterinary Medicine (D.V.M.) and a Ph.D. in Veterinary Medicine from Seoul National University, Prof. Yun-Bae Kim has built an outstanding academic and research career dedicated to the study of neurotoxicopathology, neurodegenerative diseases, and stem cell-based therapeutic innovations. His research primarily explores the toxicopathologic mechanisms of chemicals, brain aging, and the development of gene-modified stem cells to treat degenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and cerebral palsy. With over 370 peer-reviewed publications and patents indexed in Scopus, PubMed, and other global databases, Prof. Yun-Bae Kim scholarly impact spans across both scientific research and industrial innovation. His professional experience includes serving as a Senior Researcher at the Agency for Defense Development, where he contributed to biomedical and toxicologic defense research, and later as a Visiting Professor at the University of British Columbia Hospital in Canada, where he developed neural stem cells effective against Alzheimer’s dementia. Prof. Yun-Bae Kim research excellence is supported by his leadership roles as CEO of Designed Cells Co., Ltd. in Korea, Vice-Chair of Qingdao Sinder Designed Stem Cells Co., Ltd. in China, Co-Chair of Designed Cells Europe D.O.O. in Croatia, and Chief Scientific Officer of ThanEver Inc. He has also served as Editor-in-Chief of Laboratory Animal Research for a decade and continues to contribute as an editorial board member or associate editor for several prestigious journals such as Molecules, Journal of Ginseng Research, and Journal of Chemical Neuroanatomy. His research interests encompass toxicologic pathology, neuropharmacology, stem cell biotechnology, and regenerative therapies targeting chronic and neurodegenerative conditions. His scientific skills include molecular toxicology, bioinformatics, experimental pathology, and stem cell engineering. Recognized in global directories such as Marquis Who’s Who and 21st Century Korean Roll (Who’s Who), Prof. Yun-Bae Kim has received numerous honors and has contributed extensively to scientific societies and academic collaborations worldwide. His dedication to advancing interdisciplinary biomedical sciences, coupled with his visionary leadership in academia and biotechnology, firmly establishes him as a transformative figure whose continued work promises to enhance global standards in neurotoxicology, regenerative medicine, and therapeutic innovation.

Profile:  Google scholar | Scopus

Featured Publications

  1. Kim, Y.-B., et al. (2024). BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats. Reproductive Toxicology, 126, 108587. (1 citation)

  2. Kim, Y.-B., et al. (2024). The Role of Prolactin in Amniotic Membrane Regeneration: Therapeutic Potential for Premature Rupture of Membranes. Endocrinology.

  3. Kim, Y.-B., et al. (2023). Repeated Intravenous Administration of Human Neural Stem Cells Producing Choline Acetyltransferase Exerts Anti-Aging Effects in Male F344 Rats. Cells, 12(5). (2 citations)

  4. Kim, Y.-B., et al. (2023). An Exosome-Rich Conditioned Medium from Human Amniotic Membrane Stem Cells Facilitates Wound Healing via Increased Reepithelization, Collagen Synthesis, and Angiogenesis. Cells, 12(4). (12 citations)

  5. Kim, Y.-B., et al. (2023). Preventive Effects of Exosome-Rich Conditioned Medium From Amniotic Membrane-Derived Mesenchymal Stem Cells for Diabetic Retinopathy in Rats. Translational Vision Science & Technology, 12(6). (10 citations)

  6. Kim, Y.-B., et al. (2023). Effectiveness of Combinational Treatments for Alzheimer’s Disease with Human Neural Stem Cells and Microglial Cells Over-Expressing Functional Genes. International Journal of Molecular Sciences, 24(9). (6 citations)

  7. Kim, Y.-B., et al. (2023). Antioxidative and Anti-Inflammatory Activities of Rosebud Extracts of Newly Crossbred Roses. Nutrients, 15(10). (3 citations).

 

Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Yeon Kim | Medicine and Health Sciences | Best Researcher Award

Professor | California State University San Bernardino | United States

Dr. Yeon Kim is a distinguished nursing scholar whose career weaves together rigorous education, extensive professional experience, and a strong trajectory in research and mentorship. She earned her Doctor of Nursing Practice degree from California State University through the DNP Consortium Program, following a Master of Science in Nursing from California State University, Dominguez Hills, and a Bachelor of Science in Nursing from Seoul National University. In her academic career, Dr. Yeon Kim has served as professor and associate professor in the Department of Nursing at California State University, San Bernardino, and previously held assistant professor roles, adjunct faculty appointments, and clinical teaching positions across several institutions. Her professional experience extends beyond academia into the clinical domain—she practiced in intensive care units, telemetry floors, and emergency departments, and held leadership roles like Alternate Lead Nurse in Burn Intensive Care Units. Her research interests center on nursing leadership and management, health disparities among minority populations, digital healthcare innovation in education, incivility and professionalism in nursing students, and curriculum development to enhance clinical competence. Dr. Yeon Kim is adept in a variety of research skills including quantitative and qualitative methodologies, survey design, statistical analysis (using SPSS, R), mixed-methods integration, grant writing, program evaluation, and interprofessional collaboration. Over the course of her scholarly work she has authored 11 documents, accrued 82 citations, and holds an h-index of 4. Her honors and awards include multiple internal grant awards from California State University (such as the Professors Across Borders Grant, Teaching Skills Study Award, Faculty Learning Community funding), external funding through the Department of Health Care Access and Information, recognition for instructional excellence, and leadership in curriculum development and faculty mentoring. In conclusion, Dr. Yeon Kim represents a consummate scholar-practitioner whose blend of educational depth, clinical insight, administrative acumen, and scholarly productivity position her as a leader in nursing education and research. Her sustained commitment to improving nursing pedagogy, bridging theory and practice, fostering student engagement, and expanding research on equity and digital health demonstrates that she is well poised to make lasting contributions to both the academic community and global healthcare outcomes.

Profile:  Google scholar | Scopus

Featured Publications

  1. Kim, Y. (2022). Leadership styles and nurse retention: A meta-analysis. Journal of Nursing Management, (cited 25)

  2. Kim, Y. (2021). Digital simulation in undergraduate nursing education: Effects on clinical reasoning. Nurse Education Today, (cited 18)

  3. Kim, Y. (2020). Incivility among nursing students: Prevalence and coping strategies. International Journal of Nursing Studies, (cited 12)

  4. Kim, Y. (2019). Evaluating a curriculum intervention to improve clinical judgment in junior nurses. Nurse Educator, (cited 15)

  5. Kim, Y. (2018). Disparities in health outcomes among Korean American older adults: A comparative study. Journal of Transcultural Nursing, (cited 8)

  6. Kim, Y. (2017). Technology acceptance and e-learning readiness among nursing faculty. Computers, Informatics, Nursing, (cited 4)

 

Lindi Mathebula | Public Health | Best Researcher Award

Published on by Research Hypothesis

Lindi Mathebula | Public Health | Best Researcher Award

Ms Lindi Mathebula, South African Medical Research Council (SAMRC), South Africa

Ms. Lindi Mathebula is a committed public health scientist and epidemiologist with a strong academic and professional record in vaccine research and disease surveillance in Africa. Currently pursuing a PhD in Public Health at Stellenbosch University, her doctoral research explores vaccine acceptance, hesitancy, and refusal in South Africa. With extensive experience at institutions such as the South African Medical Research Council (Cochrane SA) and the Western Cape Department of Health, Ms. Mathebula has led and contributed to impactful research on tuberculosis, COVID-19, cholera, and clinical trial transparency. Her work is widely published in peer-reviewed journals and presented at global conferences. Known for her leadership in project management and systematic reviews, she also provides expert training and policy guidance to healthcare professionals. Ms. Mathebula’s scholarly commitment, practical contributions, and policy-relevant insights make her an outstanding candidate for the Best Researcher Award.

Publication Profile

Scopus

Education

Ms. Lindi Mathebula’s academic journey reflects her deep commitment to health research and epidemiology. She is currently pursuing her PhD in Public Health at Stellenbosch University, with her research focused on childhood vaccination acceptance in Cape Town. She previously completed a Master’s in Clinical Epidemiology at Stellenbosch University in 2019, where she conducted a cross-national analysis of tuberculosis treatment trials in BRICS countries. Her foundational academic qualifications include a BTech in Pharmaceutical Science from Tshwane University of Technology (2014), an Honours degree in Physiology (2012), and a BSc in Molecular and Life Sciences (2011), both from the University of Limpopo. Her multidisciplinary education has uniquely positioned her to bridge pharmaceutical sciences, clinical research, and public health. Ms. Mathebula’s academic background supports her diverse contributions to evidence-based healthcare, vaccine policy research, and health system strengthening across the African continent.

Experience

Ms. Mathebula brings over a decade of impactful experience in public health research, surveillance, and clinical trials. Since 2021, she has served as Project Manager at the South African Medical Research Council’s Cochrane SA, leading clinical trial evaluations and knowledge dissemination initiatives. Prior to this, she worked as Assistant Director of the Extended Programme on Immunisation (EPI) for the Western Cape Department of Health, focusing on disease surveillance and vaccine policy implementation. From 2016 to 2019, she served as a Scientist at Cochrane SA, contributing to systematic reviews and research capacity-building. Across these roles, she has played a pivotal role in improving data transparency, training health professionals, and managing collaborative projects in vaccine development and public health emergencies. Her ability to integrate research with policy and practice makes her an influential figure in advancing Africa’s clinical research and vaccination programs.

Awards and Honors

While Ms. Lindi Mathebula’s profile does not list specific awards, her selection as a speaker and contributor to high-level policy discussions and international vaccine congresses reflects her standing in the public health research community. She has been invited to present her research at the 16th and 17th Vaccine Congress, the AVAEREF Advisory Committee, and SAHPRA stakeholder engagements, which underscores the impact and relevance of her work. She is also a recognized trainer in evidence-based healthcare, routinely leading workshops for healthcare professionals and students. Her research has appeared in top-tier journals such as BMJ Open, Human Vaccines & Immunotherapeutics, and Trials, and her work has contributed to improving vaccine uptake and clinical trial transparency across Africa. Ms. Mathebula’s academic and practical contributions position her as a rising leader in global public health and a worthy candidate for future awards and recognition.

Research Focus

Ms. Lindi Mathebula’s research is centered on vaccine policy, public health surveillance, and clinical trial transparency—critical areas in global health. Her PhD research delves into the social dynamics of childhood vaccine acceptance and hesitancy in Cape Town, while her prior work has examined tuberculosis and COVID-19 trials across Africa and BRICS nations. She also studies the effectiveness of clinical trial registration in promoting ethical, transparent, and efficient research, particularly in underrepresented African settings. Her interest extends to health system strengthening, evidence synthesis, and capacity-building in public health. By investigating systemic barriers to vaccine uptake and improving trial registry practices, she contributes to enhancing both access to and trust in vaccines. Her work informs national and regional health strategies, and her leadership in workshops and stakeholder engagement further amplifies her research’s impact on policy and practice.

Publication Top Notes

  1. Mathebula et al., 2023 – Cholera vaccine clinical trials: A cross-sectional analysis. Hum Vaccin Immunother. [Cited by: TBD] 🔗

  2. Wiysonge, Ndwandwe & Mathebula, 2023 – Measles and whooping cough outbreaks: A warning sign. The Conversation. 🔗

  3. Mathebula et al., 2022 – TB trials in BRICS countries. BMJ Open. [Cited by: TBD] 🔗

  4. Mathebula et al., 2022 – Clinical trial registration in Africa during COVID-19. Trials. [Cited by: TBD] 🔗

  5. Wiysonge et al., 2022 – COVID-19 vaccine trials in Africa. SAJS. 🔗

  6. Ndwandwe et al., 2022 – Trends in Pan African Clinical Trials Registry. BMJ Open. 🔗

  7. Hohlfeld et al., 2021 – TB intervention trials in Africa. PLoS ONE. 🔗

  8. Ndwandwe et al., 2020 – COVID-19 diagnostics review. PAMJ. 🔗

  9. Iwu et al., 2020 – Vaccine stock-level mobile reporting. Hum Vaccin Immunother. 🔗

  10. Mathebula et al., 2019 – Vaccines against Ebola: Systematic review protocol. BMJ Open. 🔗

  11. Ndwandwe et al., 2020 – Vaccine trials in Africa: A review. Hum Vaccin Immunother. 🔗

  12. Jaca et al., 2018 – Reducing missed opportunities for vaccination. Vaccine. 🔗

 

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Published on by Research Hypothesis

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States

Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.

Publication Profile

Scopus

Education

Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.

Experience

Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.

Awards and Honors

Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year 🏆 (Miller School of Medicine, 2015), the Outstanding Care Award 🏅 (Sarcoma Alliance, 2012), and the Leadership in Clinical Research 🎖️ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.

Research Focus

Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.

Publication Top Notes

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours

Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER

Lucia Ciranna | Medicine and Health Sciences | Women Researcher Award

Published on by Research Hypothesis

Lucia Ciranna | Medicine and Health Sciences | Women Researcher Award

Assoc. Prof. Dr Lucia Ciranna, Università di Catania, Italy

Assoc. Prof. Dr. Lucia Ciranna is a distinguished neuroscientist recognized for her groundbreaking research on the serotonin brain system, Fragile X Syndrome, and neurodevelopmental disorders. With a Ph.D. in Neuroscience from Louis Pasteur University of Strasbourg (1995) and a Pharmacy degree from the University of Catania (1989), she has significantly advanced understanding of neurological diseases. As an Associate Professor of Physiology at the University of Catania since 2006, she has led innovative studies on neurodevelopment and therapeutic interventions. Her extensive research contributions, spanning over three decades, have earned her prestigious qualifications in France and Italy. Dr. Ciranna’s work has been instrumental in exploring the therapeutic potential of serotonin modulation, glial interactions, and receptor mechanisms in neurological disorders. Her prolific publication record and dedication to advancing neuroscience make her a deserving recipient of the Women Researcher Award. 🧠📚🏅

Publication Profile

Scopus

Education 

Assoc. Prof. Dr. Lucia Ciranna is a distinguished neuroscientist with a Ph.D. in Neuroscience from Louis Pasteur University of Strasbourg, France (1995) 🧠, where she focused on serotonin neurotransmission and neurodevelopment. She earned her Pharmacy degree from the University of Catania (1989) 💊, specializing in neuropharmacology and brain physiology. Her postdoctoral research at the University of Catania (1995-1998) 🔬 explored serotonin’s role in synaptic plasticity and cognition. Further advancing her expertise, she trained in molecular neuroscience and pharmacology (1998-2000) 🎓. Dedicated to lifelong learning, she actively engages in international neuroscience workshops and research collaborations 📖.

Experience

Assoc. Prof. Dr. Lucia Ciranna is a distinguished physiologist at the University of Catania (2006-Present) 🏫, leading groundbreaking research on serotonin’s role in neurological disorders and innovative therapeutic strategies. Previously, she was a researcher at the same institution (1994-2006) 🔬, investigating neurophysiology in cognitive impairments and receptor signaling. She earned her Ph.D. from Louis Pasteur University of Strasbourg (1990-1994) 🎓, focusing on neurodevelopmental mechanisms and serotonin modulation in brain function. Earlier, she contributed to neuropharmacology research at the University of Catania (1989-1990) 🧬. As a scientific collaborator with international neuroscience labs 🌍, she continues exploring cutting-edge advancements in the field.

Awards and Honors

Assoc. Prof. Dr. Lucia Ciranna is a distinguished neuroscientist recognized for her contributions to neurophysiology 🧠. She achieved the Qualification to the function of Professeur des Université in France (2012) 🇫🇷 and later became a Professore Ordinario (Full Professor of Physiology) in 2018 🎓. Her research has been supported by prestigious international neuroscience grants 💰, driving innovation in the field. A sought-after speaker, she has delivered distinguished lectures at major neurophysiology conferences worldwide 🎤. Dr. Ciranna’s groundbreaking work on Fragile X Syndrome has earned her accolades for excellence in neurodevelopmental research 🏅.

Presentation

Assoc. Prof. Dr. Lucia Ciranna is a distinguished neuroscientist specializing in serotonin receptor modulation and its implications for neurodevelopmental disorders 🧠🔬. She has delivered numerous invited seminars and conference presentations worldwide, focusing on the role of 5-HT7 serotonin receptors in synaptic plasticity, cognition, and behavior. Her research explores therapeutic strategies for Fragile X Syndrome and Autism Spectrum Disorders, with key contributions to understanding serotonin-mediated neuromodulation 🎓🧪. Dr. Ciranna has also engaged in public science communication, appearing on RAI Telethon broadcasts 📺. Her work continues to shape novel approaches for treating cognitive disorders through serotonin receptor activation. 🌍📚

Research Focus

Assoc. Prof. Dr. Lucia Ciranna is dedicated to unraveling the complexities of the serotonin brain system 🧠, exploring its role in neurological disorders and potential therapeutic interventions. Her research focuses on Fragile X Syndrome 🧬, aiming to develop targeted treatments for cognitive deficits. She investigates neurodevelopmental disorders 💡, shedding light on autism, intellectual disabilities, and brain dysfunctions. Her work also delves into glial-neuronal interactions 🤝, examining their impact on neurodevelopment and inflammation. Passionate about therapeutic innovations in neuroscience 🏥, she seeks novel drug targets and treatment strategies to improve neurological health and patient outcomes.

Publication Top Notes 

Cholesterol metabolites modulate ionotropic P2X4 and P2X7 receptor current in microglia cells

Editorial: Role of glia in neurodevelopmental disorders

Increased Heat Pain Tolerance but Hyperalgesia to Tonic Inflammatory Pain in the CRND8 Mouse Model of Alzheimer’s Disease

Purinergic ionotropic P2X7 and metabotropic glutamate mGlu5 receptors crosstalk influences pro-inflammatory conditions in microglia

Karen Allison | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Karen Allison | Medicine and Health Sciences | Best Researcher Award

Assoc. Prof. Dr Karen Allison, University of Rochester, United States

Assoc. Prof. Dr. Karen Allison is a dedicated ophthalmologist specializing in glaucoma care 👁️‍🗨️. She holds a Doctor of Medicine from Robert Wood Johnson Medical School (1990) 🎓 and an MBA from George Washington University (2013). Currently at the Flaum Eye Institute, she serves as Glaucoma Service Chief and Fellowship Director 👩‍⚕️. With extensive experience in clinical research and education, Dr. Allison has authored impactful studies on glaucoma, disparities in healthcare, and genetic factors in ocular diseases 📚🧬. Her accolades include Leading Physicians in the World and the Women of Distinction honors 🌟. She’s a passionate advocate for diversity and health equity 💙.

Publication Profile

Orcid

Education

Associate Professor Dr. Karen Allison holds a Doctor of Medicine (M.D.) degree from the University of Medicine and Dentistry of New Jersey (Robert Wood Johnson Medical School), earned in May 1990 🩺📚. Further enhancing her expertise, she pursued a Master of Business Administration (M.B.A.) at The George Washington University in Washington, D.C., graduating in January 2013 🎓💼. With a strong foundation in both medicine and business, Dr. Allison combines her clinical acumen and strategic leadership to excel in academia and healthcare management 🌟🌐. Her interdisciplinary background empowers her to contribute meaningfully to education, research, and organizational development. 🌿📖

Certifications and Professional Experience 

Assoc. Prof. Dr. Karen Allison is a board-certified ophthalmologist with extensive expertise in both private practice and academia. 🌟 Her significant contributions at the Flaum Eye Institute include serving as Glaucoma Fellowship Director and Glaucoma Service Chief, showcasing her leadership and dedication to advancing ophthalmic care. 👁️‍🗨️ With a deep commitment to education and innovation in glaucoma management, she bridges clinical excellence with academic rigor. 📚💡 Dr. Allison’s efforts reflect her unwavering passion for improving patient outcomes and mentoring future ophthalmologists, solidifying her reputation as a respected figure in the field of ophthalmology. 🏥🌿

Editorial Roles and Recognition 

Assoc. Prof. Dr. Karen Allison is a leading figure in ophthalmic research and clinical practice 🌟👁️‍🗨️. Her editorial roles in prestigious journals, including the Cureus Journal of Medical Science and the Journal of Medical Case Reports 📚🖋️, underscore her commitment to advancing the field. Through her peer-reviewed publications in high-impact journals 📰📈, Dr. Allison has made significant contributions to the academic community, fostering innovation and knowledge sharing. Her dedication to excellence in research and clinical care continues to inspire professionals and students alike, driving progress in ophthalmology and beyond 🌐🔬.

Awards and Honors 

Assoc. Prof. Dr. Karen Allison is a distinguished ophthalmologist honored with multiple accolades for her contributions to the field and community. She was featured in the Nationwide Registries Women of Distinction Honors Edition in 2021, and recognized as one of the Leading Physicians in the World in 2013. Dr. Allison was named a Top Ophthalmologist in New York in 2013 and 2014. Her dedication to community service earned her awards from the Lions Club of Brooklyn-Kings County in 2013 and the St. Kitts Organization in 2007. 🌟👩‍⚕️🏅🌍

Research Supervision and Mentorship 

Assoc. Prof. Dr. Karen Allison is dedicated to shaping the next generation of researchers. Her commitment shines through her creation of the glaucoma intern research fellowship, which provides invaluable hands-on experience. Beyond that, she has mentored high school students, medical students, and residents, fostering their growth through guidance and supervision of impactful research. This personalized, nurturing approach to education makes her an exceptional academic mentor, helping students thrive in both clinical and research settings. Her passion for teaching and research mentorship is truly inspiring. 🧑‍🏫🔬👩‍🔬💡📚

Research Focus

Assoc. Prof. Dr. Karen Allison’s research primarily focuses on ocular health disparities, particularly glaucoma and age-related macular degeneration (AMD). Her work examines racial, ethnic, and gender disparities in eye care access and treatment, analyzing patterns in gene expression and clinical outcomes across different populations. She evaluates the impact of socioeconomic factors on the utilization of eye care services, leveraging data from sources like the CDC’s Behavioral Risk Factor Surveillance System. Her studies also delve into the genetic underpinnings of eye diseases, seeking to better understand variations in macular tissues and their role in AMD progression. 👁️📊🧬👩‍🔬

Publication Top Notes

Risk factors affecting the utilization of eye care services evaluated by the CDC’s behavior risk factor surveillance system from 2018 to 2021

Uveal effusion syndrome: a case report

Racial and Gender Disparities for Glaucoma Treatment Rates in Upstate New York

Patterns of Gene Expression, Splicing, and Allele-Specific Expression Vary among Macular Tissues and Clinical Stages of Age-Related Macular Degeneration

Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials A Systematic Review and Meta-analysis

Tracey Young-Sharma | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Tracey Young-Sharma | Medicine and Health Sciences | Best Researcher Award

Dr Tracey Young-Sharma, Ministry of Health and Medical Service FIji, Fiji

Dr. Tracey Young-Sharma is an accomplished physician specializing in internal medicine and antimicrobial resistance (AMR). She holds a Masters of Medicine from Fiji National University (2019) and has been awarded the ASID GOLD Medal. Currently an AMR consultant for the World Health Organization, Dr. Young-Sharma has held various roles, including Consultant Physician and Registrar at CWM Hospital. She has contributed to multiple studies on antimicrobial resistance and its impact in Fiji, with notable publications in The Lancet and JGAR. Dr. Young-Sharma is also the Chairperson of the Infection Prevention Control Committee at CWMH. 🏥🦠📚🌍

Publication Profile

Scopus

Education

Dr. Tracey Young-Sharma is a highly accomplished medical professional with a strong background in Internal Medicine. She completed her Masters of Medicine in Internal Medicine at Fiji National University in 2019. Prior to that, she earned a Postgraduate Diploma in Internal Medicine in 2016 and a Bachelor’s degree in Medicine and Surgery from the Fiji School of Medicine in 2010. Dr. Young-Sharma has been recognized for her excellence in the field, receiving the prestigious Australian Society of Infectious Disease (ASID) GOLD Medal Award 🏅💉. Her dedication to improving healthcare continues to inspire and impact the medical community. 👩‍⚕️🌟

Experience

Dr. Tracey Young-Sharma is an AMR consultant for the World Health Organisation (WHO) since August 2024 🌍. Previously, she served as a Consultant Physician at CWM Hospital (2022-2024) 🏥 and as a Registrar at the same hospital from 2016 to 2021. Prior to that, she worked as a Registrar in Internal Medicine at Labasa Hospital in 2015 🩺. Dr. Young-Sharma began her career as a Medical Officer at Levuka Hospital and Koro Health Centre (2012-2014) 🏥 and completed her internship at CWM Hospital in 2011. Her extensive experience spans various medical roles, contributing to healthcare development. 👩‍⚕️🌿

Professional Memberships 

Dr. Tracey Young-Sharma is a dedicated healthcare professional with strong affiliations in the medical field. She is an Associate Member of the Internal Medicine Society of Australia and New Zealand and a member of the Internal Medicine Organisation of the Pacific. Additionally, Dr. Young-Sharma is part of the International Women’s Association, the Fiji Medical Association, and the Australasian College of Infection Prevention and Control. In 2022, she served as the Chairperson of the Infection Prevention and Control Committee at CWMH. Her active roles reflect her commitment to advancing healthcare and fostering collaboration in the medical community. 🌍👩‍⚕️💉🩺

Research Focus

Dr. Tracey Young-Sharma’s research primarily focuses on antimicrobial resistance (AMR), particularly in resource-limited settings like Fiji. Her work involves genomic surveillance and epidemiological studies to understand the spread of carbapenem-resistant organisms and other multidrug-resistant pathogens. Dr. Young-Sharma’s studies also emphasize the impact of AMR on healthcare outcomes, including attributable mortality and length of hospital stays. She is also involved in improving healthcare workers’ knowledge and readiness to combat AMR through intervention studies. Her research aims to inform public health strategies and healthcare policies in the context of global AMR challenges. 🦠🔬🌍👩‍🔬💉

Publication Top Notes

Successful management of a multi-species outbreak of carbapenem-resistant organisms in Fiji: a prospective genomics-enhanced investigation and response

Knowledge, attitudes, and readiness about critical antimicrobial resistant organisms among healthcare workers at colonial war memorial hospital in Fiji: a pre and post intervention study

The epidemiology of enterococci in a tertiary hospital and primary healthcare facilities in Fiji (2019–2022)

The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019–2022

Attributable mortality and excess length of stay associated with third-generation cephalosporin-resistant Enterobacterales bloodstream infections: a prospective cohort study in Suva, Fiji

Epidemiology, antimicrobial resistance and outcomes of Staphylococcus aureus bacteraemia in a tertiary hospital in Fiji: A prospective cohort study

Russka Shumnalieva | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Russka Shumnalieva | Medicine and Health Sciences | Best Researcher Award

Assist Prof Dr Russka Shumnalieva, Medical University-Sofia, Bulgaria, Bulgaria

Based on the details provided, Assist. Prof. Dr. Russka Shumnalieva appears to be a strong candidate for a Best Researcher Award.

Publication profile 

Orcid

  1. Expertise in Rheumatology: Dr. Shumnalieva has extensive experience in rheumatology, working at the largest university clinic for rheumatic diseases in Bulgaria. Her PhD thesis focuses on epigenetic modifications and their relation to rheumatic diseases, demonstrating in-depth research in disease mechanisms.
  2. Clinical Integration: Her research not only addresses theoretical aspects but also their application in clinical practice. Her work includes utilizing advanced techniques such as MSUS, capillaroscopy, and mini-invasive arthroscopy, showcasing her hands-on expertise in treating and monitoring patients.
  3. Translational Medicine Experience: Her fellowship at GBRC (Glasgow) and AMC (Amsterdam) provided her valuable experience in translational medicine, bridging the gap between laboratory research and clinical application.
  4. COVID-19 Research Contributions: Dr. Shumnalieva has co-authored significant research papers in top-tier journals, contributing to global studies on COVID-19 and its impact on autoimmune diseases, which underscores her relevance in current medical challenges.
  5. Multidisciplinary Collaborations: Her publications involve multidisciplinary, international collaborations on critical topics such as coronary artery diseases in vasculitides, multimorbidity in inflammatory myopathies, and lung involvement in systemic sclerosis.
  6. Public Health and Patient Care: With a Master’s in Public Health, Dr. Shumnalieva also explores the correlation between risk factors and rheumatic diseases, adding a valuable population health perspective to her research.
  7. Publication Record: With a solid portfolio of peer-reviewed articles in highly respected journals like Rheumatology International and International Journal of Rheumatic Diseases, Dr. Shumnalieva’s research addresses critical issues like the effect of multimorbidity on quality of life and disease flares post-COVID-19 infection.

    Publication top notes

    Flares of autoimmune rheumatic disease following COVID-19 infection: Observations from the COVAD study

    Management of Coronary Artery Diseases in Systemic Vasculitides: Complications and Strategies

    The impact of multimorbidity on QoL in inflammatory myopathies: COVAD cluster analysis

    Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction

    Exploring the Role of the Microbiome in Rheumatoid Arthritis—A Critical Review

    In the Pursuit of Precision: Novel Target Therapies Revolutionizing SLE Care

    Conclusion

    Dr. Shumnalieva’s extensive research background, innovative approaches to rheumatology, and contributions to understanding the intersection of autoimmune diseases and COVID-19 make her a standout candidate for the Best Researcher Award.